NASDAQ:CVRX CVRx (CVRX) Stock Price, News & Analysis $9.61 +0.08 (+0.84%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.46▼$9.8550-Day Range$6.49▼$12.3752-Week Range$6.40▼$33.13Volume189,154 shsAverage Volume373,687 shsMarket Capitalization$207.58 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CVRx alerts: Email Address CVRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside43.6% Upside$13.80 Price TargetShort InterestBearish19.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.39) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector444th out of 936 stocksSurgical & Medical Instruments Industry58th out of 101 stocks 4.3 Analyst's Opinion Consensus RatingCVRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCVRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CVRx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.65% of the float of CVRx has been sold short.Short Interest Ratio / Days to CoverCVRx has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in CVRx has recently increased by 4.37%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCVRx does not currently pay a dividend.Dividend GrowthCVRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVRX. Previous Next 2.4 News and Social Media Coverage News SentimentCVRx has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CVRx this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for CVRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added CVRx to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CVRx insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CVRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CVRx are expected to grow in the coming year, from ($2.39) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CVRx is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CVRx is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCVRx has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CVRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About CVRx Stock (NASDAQ:CVRX)CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More CVRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVRX Stock News HeadlinesJuly 27 at 3:37 AM | markets.businessinsider.comCraig-Hallum Gives a Buy Rating to CVRx (CVRX)July 26 at 4:14 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJuly 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…July 24 at 7:38 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJuly 23, 2024 | finance.yahoo.comWhile institutions own 41% of CVRx, Inc. (NASDAQ:CVRX), private equity firms are its largest shareholders with 44% ownershipJuly 22, 2024 | americanbankingnews.comCVRx (CVRX) to Release Quarterly Earnings on MondayJuly 20, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJuly 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJuly 27, 2024 | True Market Insiders (Ad)The #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…July 18, 2024 | americanbankingnews.comCVRx, Inc. (NASDAQ:CVRX) Receives $13.80 Consensus Target Price from BrokeragesJuly 15, 2024 | globenewswire.comCVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024July 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJune 25, 2024 | globenewswire.comCVRx Announces Appointment of Robert Allen John as Chief Revenue OfficerJune 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXJune 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXMay 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXMay 22, 2024 | globenewswire.comCVRx to Present at the William Blair 44th Annual Growth Stock ConferenceSee More Headlines Receive CVRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CVRX CUSIPN/A CIK1235912 Webwww.cvrx.com Phone763-416-2840Fax763-416-2841Employees160Year FoundedN/APrice Target and Rating Average Stock Price Target$13.80 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+43.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-123.58% Pretax Margin-123.22% Return on Equity-66.05% Return on Assets-46.99% Debt Debt-to-Equity Ratio0.44 Current Ratio12.18 Quick Ratio10.87 Sales & Book Value Annual Sales$42.09 million Price / Sales4.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.63Miscellaneous Outstanding Shares21,596,000Free Float17,514,000Market Cap$207.54 million OptionableOptionable Beta1.27 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Kevin Hykes (Age 58)President, CEO & Director Mr. Jared Oasheim (Age 40)Chief Financial Officer Comp: $446.1kMr. Paul Verrastro (Age 61)Chief Marketing & Strategy Officer Comp: $529.84kMr. Paul PignatoVice President of OperationsMs. Jonelle R. Burnham (Age 53)Vice President & General Counsel Mr. Craig Palmer (Age 47)Senior Vice President of US Sales More ExecutivesKey CompetitorsNeuroPaceNASDAQ:NPCESanara MedTechNASDAQ:SMTITELA BioNASDAQ:TELABeyond AirNASDAQ:XAIRPAVmedNASDAQ:PAVMView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 8,741 shares on 7/26/2024Ownership: 0.172%Silvercrest Asset Management Group LLCBought 105,198 shares on 5/16/2024Ownership: 1.176%FourWorld Capital Management LLCBought 20,550 shares on 5/16/2024Ownership: 0.095%Johnson & JohnsonBought 607,855 shares on 5/10/2024Ownership: 19.006%Vanguard Group Inc.Bought 31,720 shares on 5/10/2024Ownership: 2.753%View All Insider TransactionsView All Institutional Transactions CVRX Stock Analysis - Frequently Asked Questions How have CVRX shares performed this year? CVRx's stock was trading at $31.44 on January 1st, 2024. Since then, CVRX stock has decreased by 69.4% and is now trading at $9.61. View the best growth stocks for 2024 here. How were CVRx's earnings last quarter? CVRx, Inc. (NASDAQ:CVRX) posted its quarterly earnings results on Tuesday, April, 30th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.51. The business had revenue of $10.77 million for the quarter, compared to analyst estimates of $11.60 million. CVRx had a negative net margin of 123.58% and a negative trailing twelve-month return on equity of 66.05%. When did CVRx IPO? CVRx (CVRX) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are CVRx's major shareholders? CVRx's top institutional shareholders include Bank of New York Mellon Corp (0.17%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Paul Verrastro and Mudit K Jain. View institutional ownership trends. How do I buy shares of CVRx? Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CVRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CVRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.